GARY ALEXANDER: Open Payments
NPI 1811967797 · GRIFFIN, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$491 in 26 payments from 15 companies in 2025. Trend: 2023 $458 · 2024 $310 · 2025 $491
Food & beverage: $491
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 4 | $90 |
| ABBVIE INC. | 3 | $59 |
| Sumitomo Pharma America, Inc. | 3 | $50 |
| PFIZER INC. | 3 | $49 |
| Novo Nordisk Inc | 2 | $41 |
| GlaxoSmithKline, LLC. | 2 | $40 |
| Noven Therapeutics, LLC | 1 | $25 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $20 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $19 |
| Amgen Inc. | 1 | $18 |
Products named: AIRSUPRA, GEMTESA, ELIQUIS, QULIPTA, Xelstrym, Ozempic, SHINGRIX, Wegovy.
Industry payments across GA — which companies pay providers there.
